Published in Cancer Weekly, June 12th, 2001
The clinical study, which will be conducted at six medical centers around the U.S., will enroll approximately 1,000 patients. It will include about 700 women with lesions that are either visible on mammogram or palpable, and who have been recommended by their physicians to have a further diagnostic procedure such as biopsy. An additional 300 women with normal mammograms will also be recruited.
The trial will investigate the ability of the NMP66 blood test to detect cancer,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.